Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

Bright Minds to discuss BMB-101 phase 2 trial Jan. 6

By The Northwire Desk — AI Analysis Jan 05, 2026 · 20:48 DRUG · 104 Bright Minds Biosciences Inc
DRUG · Price

Executive Summary

  • Bright Minds Biosciences Inc. will host a live webcast and conference call on Tuesday, Jan. 6, 2026 at 8 a.m. ET to present the top‑line results of the Phase 2 BMB‑101 trial in drug‑resistant absence seizures and developmental & epileptic encephalopathies.
  • The presentation will include a data discussion followed by a Q&A session; participants can submit questions via the webcast “questions” tab.
  • A replay of the event will be posted on Bright Minds’ investor website after the call.

Key Details

  • Event: Conference call & live webcast to disclose Phase 2 trial results for BMB‑101.
  • Date/Time: Jan. 6, 2026, 8:00 a.m. Eastern Time.
  • Access: Live stream via the “Investors” → “Events and Presentations” section of Bright Minds’ website; replay available thereafter.
  • Agenda: Presentation of trial data → Question‑and‑Answer session (questions submitted through webcast interface).
  • Trial Focus: Patients with drug‑resistant absence seizures and developmental & epileptic encephalopathies.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Bright Minds Biosciences Inc

Jan 09, 2026 · 18:00

Bright Minds closes $175-million (U.S.) public offering

Financings Jan 09, 2026 · 11:56

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Financings Jan 08, 2026 · 04:40

Bright Minds prices shares of offering at $90 each

Financings Jan 07, 2026 · 21:33

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Financings Jan 06, 2026 · 19:32

Bright Minds arranges $10M (U.S.) public offering

Financings Jan 06, 2026 · 16:35

Bright Minds' BMB-101 phase 2 shows seizure declines

Other